HIGHLIGHTS
- who: Ricardo D. Parrondo and collaborators from the (UNIVERSITY) have published the research: Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma, in the Journal: Cancers 2022, x of 24/05/2021
- what: This study had a phase I portion and a phase II portion. The aim of the phase I portion of the trial was to assess the safety and pharmacokinetics of venetoclax- dexamethasone and the primary objective of the phase II portion of the trial was to further evaluate efficacy in addition to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.